bluebird bio Inc (NAS:BLUE)
$ 0.9624 0.06 (6.64%) Market Cap: 185.69 Mil Enterprise Value: 303.88 Mil PE Ratio: 0 PB Ratio: 0.46 GF Score: 25/100

bluebird bio Inc Temporary Suspension On Phase 1/2 And Phase 3 Studies Of LentiGlobin Gene Therapy For Sickle Cell Disease (bb1111) Corporate Call Transcript

Feb 16, 2021 / 01:00PM GMT
Release Date Price: $18.41 (-37.85%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the bluebird bio conference call. (Operator Instructions)

I would now like to turn the conference over to Ms. Ingrid Goldberg, VP of IR. Please go ahead.

Ingrid Goldberg
bluebird bio, Inc. - VP of IR

Good morning, and thank you for joining today's conference call. Before we begin, I would like to remind everyone that we will make statements of the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change.

Thank you for joining. I will now turn the call over to Nick.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot